» Articles » PMID: 3289607

Biochemical Markers in Multiple Myeloma: a Multivariate Analysis

Overview
Journal Br J Haematol
Specialty Hematology
Date 1988 May 1
PMID 3289607
Citations 3
Authors
Affiliations
Soon will be listed here.
Abstract

The analysis of individual biochemical and clinical variables in 121 patients with multiple myeloma showed that serum beta 2-microglobulin (S-beta 2m) had the most significant relation to survival. Other variables such as serum thymidine kinase (S-TK), serum lactate dehydrogenase (S-LDH), S-creatinine, haemoglobin (Hb), ESR, S-albumin, age and clinical stage were also significant. No such relationship was found with M-component, presence of light chains in urine, type of secreted immunoglobulin or S-calcium. The exclusion of clinical stage in the first multivariate analysis resulted in a model consisting of S-beta 2m, age and S-TK, none of the other variables gave additional information. When in the second multivariate analysis the basic variables involved in staging procedure were excluded and clinical stage included, stage III, but not stage II, was found to give additional information to the model described above. Individual analysis of the variables showed that Hb had the most significant relation to effect of initial therapy. Other significant variables were S-TK, S-beta 2m and age. When using the multivariate approach, Hb alone was found to contain all the relevant information.

Citing Articles

Ratio of involved/uninvolved immunoglobulin quantification by Hevylite™ assay: clinical and prognostic impact in multiple myeloma.

Koulieris E, Panayiotidis P, Harding S, Kafasi N, Maltezas D, Bartzis V Exp Hematol Oncol. 2012; 1(1):9.

PMID: 23211046 PMC: 3514091. DOI: 10.1186/2162-3619-1-9.


Deoxythymidine kinase in the tumour cells and serum of patients with non-Hodgkin lymphomas.

Rehn S, Gronowitz J, Kallander C, Sundstrom C, Glimelius B Br J Cancer. 1995; 71(5):1099-105.

PMID: 7734308 PMC: 2033808. DOI: 10.1038/bjc.1995.213.


Thymidine kinase: a tumor marker with prognostic value for non-Hodgkin's lymphoma and a broad range of potential clinical applications.

Hallek M, Wanders L, Strohmeyer S, Emmerich B Ann Hematol. 1992; 65(1):1-5.

PMID: 1643153 DOI: 10.1007/BF01715117.